Report Store Get Proposal

Home Blog Respiratory diseases

Respiratory Diseases

pharma-news-for-tanabe-biogen-merck

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Tanabe Pharma Shares Encouraging Phase 3 Data for Dersimelagon in Rare Photodermatoses; Biogen’s Litifilimab Demonstrates Significant Skin Disease Reduction in Phase 2 CLE Trial; Merck’s WINREVAIR Shows Promising Phase 2 Results in CpcPH-HFpEF Population; AstraZeneca’s Tozorakimab Meets Primary Endpoints in OBERON and TITANIA Phase III COPD Trials; Amgen’s REPATHA Shows Strong Cardiovascular Risk Reduction in High-Risk Patients

Tanabe Pharma Reports Positive Phase 3 INSPIRE Results for Dersimelagon in EPP and XLP Tanabe Pharma Corporation has announced detailed findings from the Phase 3 INSPIRE trial evaluating investigational oral dersimelagon in patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). The results were shared during a late-breaking oral session at the American Academy of Dermatology Annual Meeting 2026 on March 28, 2026. Dersimelagon, a selective melanocortin 1 receptor (MC1R) agonist, successfully achieved its primary endpoint. It demonstrated a statistically significant increase in the average daily sunlight exposure time before the onset...

Explore More...

pharma-news-for-gilead-novo-vanda

Gilead Sciences to Acquire Arcellx in Strategic Move to Accelerate Anito-cel Development; Novo Nordisk Faces Setback as CagriSema Underwhelms Against Rival Therapy in Trial; Vanda Pharmaceuticals Secures FDA Approval for BYSANTI; All-oral Calquence + venetoclax Combo Clears in the US for First-line Treatment of CLL; Merck’s ENFLONSIA Demonstrates Strong Protection Against Severe RSV in Young Children Over Consecutive Seasons

medtech-news-for-medtronic-retia-medical-danaher

Medtronic Wins FDA Green Light for Stealth AXiS; Retia Medical Secures FDA 510(k) Clearance for Argos Infinity; Danaher Announces Plan to Acquire Masimo Corporation; Dynarex Introduces New Advanced Negative Pressure Therapy Device; Valcare Medical Reports First U.S. Transseptal AMEND™ Implant in Early Feasibility Study; Envoy Medical Reports Enrollment Nearly Complete for Acclaim Cochlear Implant Pivotal Trial

pharma-news-for-roche-novartis-ptc

Roche’s GAZYVA/GAZYVARO Achieves Key Phase III Success in Primary Membranous Nephropathy; Novartis’ VANRAFIA Slows Kidney Function Decline in Phase III IgA Nephropathy Trial; PTC Therapeutics Shares Latest Regulatory Developments for Translarna; BridgeBio’s Oral Infigratinib Achieves Key Body Proportionality Improvements in Phase 3 Achondroplasia Trial; Upstream Bio’s Verekitug Achieves Key Endpoints in Phase 2 Trial for Severe Asthma Treatment

$refractory-chronic-cough-treatment$

Limited Refractory Chronic Cough Treatment Landscape: LYFNUA Approval Restricted to Europe and Japan

Artificial Intelligence in Remote Patient Monitoring: Enabling Continuous, Predictive, and Personalized Care

Artificial Intelligence in Remote Patient Monitoring: Enabling Continuous, Predictive, and Personalized Care

pharma-news-for-boehringer-denali-regeneron

FDA Approves Boehringer’s JASCAYD as First New IPF Therapy in Over a Decade; Denali Therapeutics’ Tividenofusp Alfa BLA Review for Hunter Syndrome Extended by FDA; Bicara’s Ficerafusp Alfa Earns FDA Breakthrough Tag for 1L HPV-Negative Head & Neck Cancer; BeOne Medicines’ Sonrotoclax Granted FDA Breakthrough Designation for Cancer Treatment; FDA Clears LIBTAYO for Adjuvant Use in Cutaneous Squamous Cell Carcinoma

jascayd-for-ipf-treatment

Boehringer Ingelheim’s JASCAYD Brings Hope Back to IPF Patients After a Decade of Waiting

Wearables 2.0_ The Next Wave of Clinical-Grade Wearable Medical Devices-feature

Wearables 2.0: The Next Wave of Clinical-Grade Wearable Medical Devices

Smart Inhalers_ Redefining Respiratory Care with Technology and Data feature

Smart Inhalers: Redefining Respiratory Care with Technology and Data

ai-powered-point-of-care-diagnostics

The Rise of AI-Powered Point-of-Care Diagnostics: Transforming Real-Time Patient Care

dupixents-launch-in-copd

DUPIXENT’s Launch Brings Next Chapter of Biologics in COPD

insmed-brinsupri-for-ncfb

Insmed’s BRINSUPRI, the First DPP1 Inhibitor: A New Era in NCFB Treatment

pharma-news-for-precigen-regenxbio-tonix

Precigen’s PAPZIMEOS Wins Full FDA Approval for Recurrent Respiratory Papillomatosis; Tonix’s Tonmya Becomes First FDA-Approved Fibromyalgia Treatment in Over 15 Years; FDA Extends BLA Review for REGENXBIO’s RGX-121 in MPS II Patients; SystImmune’s Izalontamab Brengitecan (EGFRxHER3 ADC) Gets FDA Breakthrough Designation for EGFR-Mutated NSCLC; Soligenix Granted FDA Orphan Drug Status to SGX945 for Behçet’s Disease Therapy Following Phase II Success

asthma-treatment-gaps

Asthma Uncontrolled: Why Better Treatments Haven’t Fixed the Crisis

pharma-news-for-anbogen-bms-clarametyx

Anbogen’s ABT-301 Cleared by FDA for Phase I/II Colorectal Cancer Trial; Dyne’s DYNE-251 Gets FDA Breakthrough Tag for Duchenne Muscular Dystrophy; BMS’s BREYANZI Accepted for FDA Priority Review in MZL; Clarametyx’s CMTX-101 Earns FDA Fast Track and QIDP for Infections; Anixa Begins FDA-Approved IND Transfer for Phase II Breast Cancer Vaccine Trial

Small interfering RNA (siRNA) Therapeutics

Small interfering RNA (siRNA) Therapeutics

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly